Translucence Biosystems presents at the Society for Neuroscience's 50th Annual Meeting

Translucence Biosystems
November 10, 2021

Translucence Biosystems is honored to present at the Society for Neuroscience's 50th Annual Meeting. Our presentation is entitled, "Brain-wide cellular resolution snapshots of neuronal activity with Npas4 and cFos". Access our presentation materials below.


Recent advances in optical clearing and light sheet imaging have opened an exciting new avenue for brain-wide, cellular resolution immunostaining at the forefront of a dimensional shift from 2D to 3D histology. Providing access to the intricate anatomy of the whole intact brain, new tissue clearing methods can provide neuroscientists with unbiased and complete pictures of brain anatomy and function. With our optimized iDISCO-based clearing methods and our Mesoscale Imaging System for the ZEISS Lightsheet Z.1 microscope, we can image entire mouse brains in ~25 min. Further, our machine learning-enabled 3TK software identifies individual cells throughout the brain and aligns them to the Allen Reference Atlas to produce a regionalized read-out of cellular patterns across 100’s of brain areas. We have applied this technology to generate cellular resolution maps of neuronal activity by measuring the immediate-early gene (IEG) products Npas4 and cFos. Expression of cFos is driven by Ca 2+ - signaling downstream of neuronal activity and is commonly used to mark active neurons. However, cFos expression is also driven by cAMP elevations and signaling pathways engaged by neurotrophins or other paracrine factors. In contrast, Npas4 expression is neuron-specific and tightly tuned to Ca 2+ -dependent signaling pathways. Using our Npas4 recombinant rabbit monoclonal antibody and a commercial cFos antibody, we developed whole-brain co-staining procedures and performed experiments on mice kept in the dark and exposed to light for various periods of time. After 24 hours in the dark, we found a large number of cFos(+) neurons, yet these same neurons did not express Npas4, suggesting that factors other than neuronal activity per se drove cFos expression at baseline. After light exposure, the lower baseline expression of Npas4 supported a much larger fold-change increase in expression than with cFos, where the elevated baseline of cFos(+) cells masked the precise identification of the stimulus-related ‘trace’. The fidelity of the Npas4 response allowed our statistical anatomics tools to identify a large number of brain regions, some expected and some not, that had elevated neuronal activity after light exposure. Similarly, in Contextual Fear Conditioning experiments, home cage mice expressed much less Npas4 than cFos, allowing for more precise monitoring of changes in neuronal activity after context exposure and shock. Our pipeline for brain-wide monitoring of cFos and Npas4 expression allows for high-fidelity monitoring of neuronal activity with Npas4 and also allows for mapping responses to GPCRs or trophic factors by measuring cFos(+)/Npas4(-) neurons.

Access the presentation file here.

Ask your question

Send us your questions and we will get back to you as soon as possible

Thank you! Your submission has been received!
Something went wrong while submitting the form.
Please, contact via us direct email info@translucencebio.comand

Recent news

May 4, 2022

Co-Founder, Sunil Gandhi Ph.D., presents at the 8th Annual Bench to Bedside Symposium

Co-Founder, Sunil Gandhi Ph.D., presents at the 8th Annual Bench to Bedside Symposium hosted by the Gavin Herbert Eye Institute at the University of California, Irvine School of Medicine.
Angela Prvulovic
September 29, 2021

Translucence Biosystems is a 2021 High Tech Awards finalist

Translucence Biosystems is a finalist in the Outstanding Emerging Technology Company category at Octane OC's 2021 High Tech Awards (HTA). Special thanks to University Lab Partners for making our work possible!
Damian Wheeler
September 21, 2021

Co-Founder, Sunil Gandhi Ph.D., presents at Research Innovation Spotlight on Neuroscience hosted by Alliance for SoCal Innovation & BioscienceLA

Sunil Gandhi Ph.D. discusses novel imaging technology that has the potential to dramatically enhance how researchers can locate drug effects in the central nervous system (CNS) for preclinical studies.
Angela Prvulovic